Trial Profile
A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine/insulin lispro (Primary) ; Insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Adocia
- 25 Jan 2018 Primary endpoint has been met. (Cmax_total), as reported in an Adocia media release.
- 25 Jan 2018 Primary endpoint has been met. (AUC last_total), as reported in an Adocia media release.
- 25 Jan 2018 Results published in an Adocia Media Release